FBIOX — Select Biotechnology Portfolio
Data updated: 2026-07-24
FBIOX — Select Biotechnology Portfolio data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $5.27B AUM · 0.62% expense ratio · 55.7% 1-yr return. From SEC regulatory filings.
FBIOX Fund Overview
FBIOX — Select Biotechnology Portfolio is a US mutual fund managed by Fidelity Select Portfolios, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Fidelity Select Portfolios
- Category: United States Health Care Equity
- Assets under management: $5.27B
- 1-year return: 55.7%
- Ticker: FBIOX
- SEC CIK: 0000320351
- SEC series ID: S000007486
- Share class ID: C000020460
FBIOX Holdings
Top 10 holdings of Select Biotechnology Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Krystal Biotech, Inc. | 10.58% |
| Abbvie, Inc. | 9.22% |
| Amgen, Inc. | 6.53% |
| Gilead Sciences, Inc. | 4.82% |
| Fidelity Revere Street Trust | 3.35% |
| Alnylam Pharmaceuticals, Inc. | 2.93% |
| Praxis Precision Medicines Inc. | 2.47% |
| Insmed, Inc. | 2.25% |
| Argenx SE | 2.25% |
| Ascendis Pharma A/s | 2.04% |
FBIOX Portfolio Allocation
Asset-class allocation of Select Biotechnology Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 3.5% |
FBIOX Performance
Total returns for FBIOX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 6.2% |
| 1 year | 55.7% |
| 3 years (annualised) | 18.9% |
| 5 years (annualised) | 6.7% |
FBIOX Risk Information
Risk metrics for FBIOX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 12.6%
FBIOX Costs and Fees
FBIOX costs about $62 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.62%
- Gross expense ratio: 0.62%
- Portfolio turnover: 45%
- Brokerage commissions: 3.29 bps of average net assets (SEC N-CEN)
FBIOX Cashflows
Over the 12 months to 2026-02, Select Biotechnology Portfolio had net outflows of $231.79M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | −$39.35M |
| 2026-01 | −$37.63M |
| 2025-12 | $116.04M |
| 2025-11 | $22.99M |
| 2025-10 | −$32.29M |
| 2025-09 | −$53.86M |
FBIOX Debt Constituents
No individual debt constituents are reported in Select Biotechnology Portfolio's latest SEC N-PORT filing.
FBIOX Prospectus and SEC Filings
Official Select Biotechnology Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.